Historical perspective and future direction of thrombolysis research: The re-discovery of plasmin

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 1 S, 2011, Pages 364-373

  Marder, V J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Historical; Plasmin; Plasminogen activators; Thrombolysis

Indexed keywords

DESMOTEPLASE; PLACEBO; PLASMIN; PLASMINOGEN ACTIVATOR; RECOMBINANT PLASMINOGEN ACTIVATOR; STAPHYLOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANGIOPLASTY; BIOCHEMISTRY; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CATHETER DIRECTED THROMBOLYSIS; CATHETERIZATION; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG EFFICACY; ENDOVASCULAR SURGERY; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLICATION; RECANALIZATION; REPERFUSION; REVIEW; STROKE; THROMBOSIS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FIBRINOLYSIN; FIBRINOLYSIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; THROMBOSIS;

EID: 79960618940     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04370.x     Document Type: Review

References (142)

1. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502.
2. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal deoxyribonuclease on fibrinous, purulent and sanguineous pleural exudations. J Clin Invest 1949; 28: 173-90.
3. Cliffton EE. The use of plasmin in humans. Ann N Y Acad Sci 1957; 68: 209-29.
4. Boyles PW, Meyer WH, Graff J, Ashley CC, Ripic RG. Comparative effectiveness of intravenous and intra-arterial fibrinolysin therapy. Am J Cardiol 1960; 6: 439-40.
5. Koller F. The development of our knowledge of fibrinolysis. Am J Cardiol 1960; 6: 367-70.
6. MacFarlane RG. The development of ideas on fibrinolysis. Br Med Bull 1964; 20: 173-8.
7. Cliffton EE. Review of clinical experience with clot-lysing agents. Am J Cardiol 1960; 6: 476-86.
8. Sherry S. Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J 1981; 102: 1134-8.
9. Sherry S. The origin of thrombolytic therapy. J Am Coll Cardiol 1989; 14: 1085-92.
10. Braunwald E. Personal reflections on efforts to reduce ischemic myocardial damage. Cardiovasc Res 2002; 56: 332-8.
11. Collen D. Human tissue-type plasminogen activator: from the laboratory to the bedside. Circulation 1985; 72: 18-20.
12. Collen D, Lijnen HR. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2004; 2: 541-6.
13. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93: 627-30.
14. Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol 2009; 29: 1151-5.
15. Verstraete M. The fibrinolytic system: from Petri dishes to genetic engineering. Thromb Haemost 1995; 74: 25-35.
16. Kennedy JW. 50th anniversary historical article. Thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 1999; 33: 1829-32.
17. van de Werf FJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost 2009; 7: 14-20.
18. Rosch J, Keller FS, Kaufman JA. The birth, early years, and future of interventional radiology. J Vasc Interv Radiol 2003; 14: 841-53.
19. Ouriel K. A history of thrombolytic therapy. J Endovasc Ther 2004; 11(Suppl II): II128-33.
20. Morgagni JB. De sedibus et causis morborum per anatomen indagatis. Lovanii: Apud M.C. Compere, 1761.
21. Denis PS. Essai sur l'application de la chimie a l'etude physiologique du sang de l'homme. Paris: JB Ballièere, 1838.
22. Denys J, De Marbaix H. Les peptonisations provoquees par le chloroforme. Cellule 1889; 5: 197-251.
23. Skundina M, Rusakow A, Ginsburg R, Bocarow A. Die biochemischen Veranderungen im Leichenblut. Sovet Chir 1935; 6: 78.
24. Yudin SS. Transfusion of cadaver blood. JAMA 1936; 106: 997-9.
25. Dastre A. Fibrinolyse dans le sang. Arch Norm Pathol 1893; 5: 661-3.
26. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: I. Isolation and characterization of fibrinolysin. J Exp Med 1934; 60: 239-54.
27. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: II. Nature of the reaction. J Exp Med 1934; 60: 255-67.
28. Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 1941; 42: 109-16.
29. Tagnon JG, Davidson CS, Taylor FHL. The coagulation defect in hemophilia: a comparison of the proteolytic activity of chloroform preparations of hemophilic and normal plasma. J Clin Invest 1943; 22: 127-34.
30. Christensen LR, MacLeod CM. A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J Gen Physiol 1945; 28: 559-83.
31. Christensen LR. Streptococcal fibrinolysis: a proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysis. J Gen Physiol 1945; 28: 363-83.
32. Astrup T, Permin PM. Fibrinolysis in the animal organism. Nature 1947; 159: 681-2.
33. Astrup T. Activation of a proteolytic enzyme in blood by animal tissue. Biochem J 1951; 50: 5-11.
34. Mullertz S. A plasminogen activator in spontaneously active human blood. Proc Soc Exp Biol Med 1953; 82: 291-5.
35. Mullertz S, Lassen M. An activator system in blood indispensable for formation of plasmin by streptokinase. Proc Soc Exp Biol Med 1953; 82: 264-8.
36. Williams JR. The fibrinolytic activity of urine. Br J Exp Pathol 1951; 32: 530-7.
37. Sobel GW, Mohler SR, Jones NW, Dowdy ABC, Guest MM. Urokinase: an activator of plasma profibrinolysin extracted from urine. Am J Physiol 1952; 171: 768-9.
38. Lack CH. Staphylokinase: an activator of plasma protease. Nature 1948; 161: 559.
39. Ratnoff OD, Lepow IH, Pillemer L. The multiplicity of plasmin inhibitors in human serum, demonstrated by the effect of primary amino compounds. Bull Johns Hopkins Hosp 1954; 94: 169-79.
40. Kline DL. Purification and crystallization of plasminogen (profibrinoloysin). J Biol Chem 1953; 204: 949-55.
41. Guest MM, Celander DR. Urokinase: physiologic activator of profibrinolysis. Tex Rep Biol Med 1961; 19: 89-105.
42. MacFarlane RG, Biggs R. Fibrinolysis: its mechanism and significance. Blood 1948; 3: 1167-87.
43. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202: 498-9.
44. Davie EW, Ratnoff D. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-2.
45. Johnson AJ, Tillett WS. Lysis in rabbits of intravavascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952; 95: 449-64.
46. Grossi CE, Cliffton EE. The lysis of arterial thrombi in rabbits and dogs by use of activated human plasminogen (fibrinolysin) (plasmin). Surgery 1955; 37: 794-802.
47. Ruegsegger P, Nydick I, Abarquez R, Reichel F, Cliffton EE, LaDue JS. Effect of fibrinolytic (plasmin) therapy on the physiopathology of myocardial infarction. Am J Cardiol 1960; 6: 519-24.
48. 131 labeled fibrinogen. Fed Proc 1956; 15: 396.
49. Verstraete M, Vermylen J, Amery A. Enzymatic clot dissolution in man: a new therapeutic approach. Acta Clin Belg 1964; 19: 271-90.
50. Douglas AS, McNicol GP. Thrombolytic therapy. Br Med Bull 1964; 20: 228-32.
51. Boucek RJ, Murphy WP. Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Am J Cardiol 1960; 6: 525-33.
52. Cliffton EE. The use of plasmin in humans. Am J Cardiol 1960; 6: 546-51.
53. Sherry S. Fibrinolytic activity of streptokinase activated human plasmin. J Clin Invest 1954; 33: 1054-63.
54. Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959; 38: 1086-95.
55. Wiman B, Collen D. Molecular model of physiological fibrinolysis. Nature 1978; 272: 549-50.
56. Johnson AJ, McCarty WR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest 1959; 38: 1627-43.
57. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. Treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 1958; 71: 287-96.
58. Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111: 31-7.
59. Urokinase-Pulmonary Embolism Trial Study Group. Urokinase-pulmonary embolism trial: phase i results. JAMA 1970; 214: 2163-72.
60. Urokinase-Streptokinase Pulmonary Embolism Trial. Phase II results: a national cooperative trial. JAMA 1974; 229: 1606-13.
61. The Urokinase Pulmonary Embolism Trial. A national cooperative study. Circulation 1973; 47(Suppl II): 1-108.
62. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
63. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadavskaia GV, Ruda MI. Intracoronary administration of fibrinolysin in acute myocardial infarction. Ter Arkh 1976; 48: 8-19.
64. Rentrop P, Blanke H, Kostering K, Karsch KR. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase in combination with transluminal recanalization. Clin Cardiol 1979; 2: 354-63.
65. Schroder R, Biamino G, von Leitner ER, Linderer T, Bruggemann T, Heitz J, Vohringer HF, Wegscheider EI. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation 1983; 63: 536-48.
66. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 156: 7035-41.
67. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activactor cDNA in E. coli. Nature 1983; 201: 214-21.
68. Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981; 291: 590-1.
69. Weimar W, Stibbe J, van Seyen AJ, Biliau A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2: 1018-20.
70. van de Werf F, Bergmann SR, Fox KAA, de Geest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69: 605-10.
71. Gruppo Italiano per lo Studio Della Streptochinase Nell'infarto Miocardico. Effectiveness of intravenous thromblytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
72. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-54.
73. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. for ASSET (Angelo-Scandinavian Study of Early Thrombolysis) Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2: 525-30.
74. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after AMI: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545-9.
75. Gruppo Italiano per lo Studio Della Sopravvivenza nell'Infarto Miocardioco (GISSI). GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12, 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
76. The International Study Group. In-hospital mortality and clinical course of 20, 891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-5.
77. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
78. Hennekens CH, O'Donnell CJ, Ridker PM, Marder VJ. Current issues concerning thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1995; 25(Suppl): 18S-22S.
79. Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-22.
80. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
81. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence of thrombolytic therapy for acute ischemic stroke. Lancet 1997; 350: 607-14.
82. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276: 961-6.
83. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-29.
84. Katzen BT, van Breda A. Low dose streptokinase in the treatment of arterial occlusions. AJr. Am J Roentgenol 1981; 136: 1171-8.
85. McNamara T, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high dose urokinase. AJr. Am J Roentgenol 1985; 144: 769-75.
86. Ouriel K, Shortell CK, De Weese JA, Green RM, Francis CW, Azodo MVU, Gutierrez OS, Manzione JV, Cox C, Marder VJ. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994; 19: 1021-30.
87. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg 1994; 220: 251-66.
88. Francis CW. Ultrasound-enhanced thrombolysis. Echocardiography 2001; 18: 239-46.
89. Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 1994; 84: 680-6.
90. Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RAF, Friedman PA. Isolation, characterization and cDNA cloning of a vampire bat salibary plasminogen activator. J Biol Chem 1989; 264: 17947-52.
91. Deng YZ, Reeves MJ, Jacobs BS, Birbeck GL, Kothari RU, Hickenbottom SL, Mullard AJ, Wehner S, Maddox K, Majid A; Paul Coverdell National Acute Stroke Registry Michigan Prototype Inverstigators. IV tissue plasminogen activator use in acute stroke; experience from a statewide registry. Neurology 2006; 66: 306-12.
92. Katzen IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61: 346-50.
93. Cohen JE, Itshayek E, Moskovici S, Gomori JM, Fraifeld S, Eichel R, Leker RR. State-of-the-art reperfusion strategies for acute ischemic stroke. J Clin Neurosci 2011; 18: 319-23.
94. Furlan AJ, Abou-Chebl A. The role of recombinant pro-urokinase (r-pro-UK) and intra-arterial thrombolysis in acute ischaemic stroke: the PROACT trials. Prolyse in acute cerebral thromboembolism. Curr Med Res Opin 2002; 18(Suppl 2): s44-7.
95. Nogueira RG, Liebeskind DS, Sung G, Duckwiler G, Smith WS; on behalf of the MERCI and Multi MERCI Writing Committee. Predictors of good clinical outcomes, mortality and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy. Pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI Trials. Stroke 2009; 40: 3777-83.
96. Menon BK, Kochar P, Ah-Seng A, Almekhlafi MA, Modi J, Wong JH, Hudon ME, Morrish W, Demchuk AM, Goyal M. Initial experience with a self-expanding retrievable stent for recanalization of large vessel occlusions in acute ischemic stroke. Neuroradiology 2011; Epub ahead of print.
97. Ribo M, Molina CA, Alvarez B, Rubiera M, Alvarez-Sabin J, Matas M. Intra-arterial administration of microbubbles and continuous 2-MHz ultrasound insonation to enhance intra-arterial thrombolysis. J Neuroimaging 2010; 20: 224-7.
98. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Hoye LA, Hill MD, Wojner AW; CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351: 2170-8.
99. Anderson HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS; DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-42.
100. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WE; and the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328: 673-9.
101. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018.
102. Hirsh J, Salzman EW, Marder VJ. Treatment of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd edn. Philadelphia, PA: J. B. Lippincott, Co., 1994: 1346-66.
103. Lin PH, Ochoa LN, Duffy P. Catheter-directed thrombectomy and thrombolysis for symptomatic lower-extremity deep vein thrombosis: review of current interventional treatment strategies. Perspect Vasc Surg Endovasc Ther 2010; 22: 152-63.
104. Comerota AJ, Throm RC, Mathias SD, Haughton S, Mewissen M. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg 2000; 32: 130-7.
105. Parikh S, Motarjeme A, McNamara T, Raabe R, Hagspiel K, Benenati JF, Sterling K, Comerota A. Ultrasound-accelerated thrombolysis for the treatment of deep vein thrombosis: initial clinical experience. J Vasc Interv Radiol 2008; 19: 521-8.
106. Enden T, Klow NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM; CaVenT study group. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost 2009; 7: 1268-75.
107. Grommes J, Strijkers R, Greiner A, Mahnken AH, Wittens CH. Safety and feasibility of ultrasound-accelerated catheter-directed thrombolysis in deep vein thrombosis. Eur J Vasc Endovasc Surg 2011; 41: 526-32.
108. Grewal NK, Martinez JT, Andrews L, Comerota AJ. Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity. J Vasc Surg 2010; 51: 1209-14.
109. Moudgill N, Hager E, Gonsalves C, Larson R, Lombardi J, DiMuzio P. May-Thurner syndrome: case report and review of the literature involving modern endovascular therapy. Vascular 2009; 17: 330-5.
110. Marder VJ. Foundations of thrombolytic therapy. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SJ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2006: 1739-52.
111. Marder VJ, Stewart D. Towards safer thrombolytic therapy. Semin Hematol 2002; 39: 206-16.
112. Marder VJ. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979; 90: 802.
113. Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med 1988; 318: 1512-20 and 1585-1595.
114. Thanvi BR, Treadwell S, Robinson T. Haemorrhagic transformation in acute ischaemic stroke following thrombolysis therapy: classification, pathogenesis and risk factors. Postgrad Med J 2008; 84: 361-7.
115. Wang X, Lo EH. Triggers and mediators of haemorrhagic transformation in cerebral ischaemia. Mol Neurobiol 2003; 28: 229-44.
116. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, Roine RO, Toni D; Lees KR for the SITS Investigators. Thrombolysis with alteplase 3-4.5h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-9.
117. Uyttenboogaart M, Vroomen PCAJ, Stewart RE, De Keyser J, Luijckx GJ. Safety of routine IV thrombolysis between 3 and 4.5h after ischemic stroke. J Neurol Sci 2007; 254: 28-32.
118. Dzialowski I, Pexman JHW, Barber PA, Demchuk AM, Buchan AM, Hill MD; on behalf of the CASES Inverstigators. Asymptomatic hemorrhage after thrombolysis may not be benign. Prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke 2007; 38: 75-9.
119. Toni D, Lorenzano S, Agnelli G, Guidetti D, Orlandi G, Semplicine A, Toso V, Caso V, Malferrari G, Fanucchi S, Bartolomei L, Prencipe M. Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80years in Italy. Cerebrovasc Dis 2008; 25: 129-35.
120. Singer OC, Berkefeld J, Lorenz MW, Fiehler J, Albers GW, Lansberg MG, Kastrup A, Rovira A, Liebeskind DS, Gass A, Rosso C, Derex L, Kim JS, Neumann-Haefelin T; for the MR Stroke Study Group Invertigators. Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis. Cerebrovasc Dis 2009; 27: 368-74.
121. Haley EC Jr, Thompson JLP, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B; for the Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial. Stroke 2010; 41: 707-11.
122. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, Kaste M, Lipka LJ, Pedraza S, Ringleb PA, Rowley HA, Schneider D, Schwamm LH, Leal JS, Sohngen M, Teal PA, Wilhelm-Ogunbiyi K, Wintermark M, Warach S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging of perfusion CT (DIAS-2): a prospective, randomized, double-blind, placebo-controlled study. Lancet 2009; 8: 141-50.
123. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med 1998; 338: 1105-11.
124. Agle SC, McNally MM, Powell CS, Bogey WM, Parker FM, Stoner MC. The association of periprocedural hypertension and adverse outcomes in patients undergoing catheter-directed thrombolysis. Ann Vasc Surg 2010; 24: 609-14.
125. Kim HS, Preece SR, Black JH, Pham LD, Streiff MB. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg 2008; 47: 388-94.
126. Vik A, Holme PA, Singh K, Dorenberg E, Nordhus KC, Kumar S, Hansen JB. Catheter-directed thrombolysis for treatment of deep venous thrombosis in the upper extremities. Cardiovasc Intervent Radiol 2009; 32: 980-7.
127. Broholm R, Panduro Jensen L, Baekgaard N. Catheter-directed thrombolysis in the treatment of iliofemoral venous thrombosis. A review. Int Angiol 2010; 29: 292-302.
128. Maleux G, Marchal P, Palmers M, Heye S, Herhamme P, Vaninbroukx J, Verhaeghe R. Catheter-directed thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer. Eur Radiol 2010; 20: 2293-300.
129. Dhi HJ, Huang YH, Shen T, Xu Q. Percutaneous mechanical thrombectomy combined with catheter-directed thrombolysis in the treatment of symptomatic lower extremity deep venous thrombosis. Eur J Radiol 2009; 71: 350-5.
130. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation 2006; 113: 577-82.
131. Lin PH, Annambhotia S, Bechara CF, Athamneh H, Weakley SM, Kobayashi K, Kougias P. Comparison of percutaneous ultrasound-accelerated thrombolysis versus catheter-directed thrombolysis in patients with acute massive pulmonary embolism. Vascular 2009; 17(Suppl 3): S137-47.
132. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-45.
133. Collen D. Revival of plasmin as a therapeutic agent? Thromb Haemost 2001; 86: 731-2.
134. Novokhatny VV, Jesmok G, Landskroner K, Marder VJ, Zimmerman TP. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis? Trends in Pharm Sci 2004; 25: 72-5.
135. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Relevance of plasma cogualtion for safety during plasmin administration: comparison with TPA in a model of fibrinolytic hemorrhage. Blood 2003; 101: 3002-7.
136. Marder VJ, Blinc A, Gruber T, Tratar G, Sabovic M, Starkman S, Jahan R, Duckwiler G, Vinuela F, Tateshima S, Liebeskind D, Ovbiagele B, Ali L, Kim D, Gonzalez N, Vespa PM, Saver JL. Comparison of plasmin with rt-PA in lysis of cerebral thrombo-emboli retrieved from patients with acute ischemic stroke. Stroke 2011; 42. in press.
137. Marder VJ. Preclinical studies of plasmin: superior benefit-to-risk ratio compared to tissue plasminogen activator (tPA). In: "Potential for better thrombolytic therapy: Is plasmin the answer?" Marder VJ and Novokhatny V, Guest Editors, Thromb Res 2008; 122: S9-15.
138. Marder VJ, Novokhatny V. Direct fibrinolytic agents: biochemical attributes, pre-clinical foundation and clinical potential. J Thromb Haemost 2010; 8: 433-44.
139. Nagai N, Demarsin E, van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 2003; 1: 307-13.
140. Toombs CF. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis 2001; 31: 141-7.
141. Hunt JA, Petteway SR Jr, Scuderi P, Novokhatny V. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin. Thromb Haemost 2008; 100: 413-9.
142. Marder VJ, Manyak S, Gruber T, Goyal A, Moreno G, Hunt J, Bromirski J, Scuderi P, Petteway SR, Novokhatny V. Hemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5. Thromb Haemost 2010; 104: 780-7.